Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CD44 | P16070 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101429 | 0.86 | HRH3 (0.46) | HRH3CD44PRCPHTR6TIPARP | |
| SCHEMBL17585080 | 0.85 | HRH3 (0.49) | HRH3CD44PRMT5CD274PNMT | |
| Hydrochloric Acid SCHEMBL5441185 | 0.84 | HRH3 (0.48) | HRH3CD44PRMT5CD274PNMT | |
| SCHEMBL20983791 | 0.84 | HRH3 (0.51) | HRH3CD44PRMT5CD274PNMT | |
| SCHEMBL4718360 | 0.84 | HRH3 (0.48) | HRH3CD44PRMT5CD274PNMT | |
| SCHEMBL8185445 | 0.81 | CD44 (0.51) | HRH3CD44PRMT5CD274PNMT | |
| Ammonia Solution, Strong SCHEMBL8189446 | 0.80 | CD44 (0.50) | HRH3CD44PRMT5CD274PNMT | |
| SCHEMBL5016341 | 0.78 | RXRB (0.48) | CD44HTR6 | |
| SCHEMBL22319931 | 0.78 | ADRA2A (0.58) | HRH3CD44PRMT5PNMTMAOB | |
| SCHEMBL17585081 | 0.78 | CD44 (0.47) | HRH3CD44PRMT5CD274PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940819-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | HRH3 4640/4885CD44 4752/4885PRMT5 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.